Oct 17 (Reuters) - 3d Signatures Inc DXD.V :
* 3DS plans to announce a clinical trial for a Hodgkin's Lymphoma precision medicine test in coming months
* Expects to engage laboratory partner in validation, approval of a Hodgkin's Lymphoma Laboratory Developed Test (LDT) for Canada in 2017 Source text for Eikon: ID:nCCNhSv1W Further company coverage: DXD.V